Fonte: Oncotarget. Unidade: FM
Assuntos: NEOPLASIAS MAMÁRIAS, FATORES DE RISCO, BIOMARCADORES, EVENTO ADVERSO A MEDICAMENTO, DOENÇAS CARDIOVASCULARES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RIGAUD, Vagner Oliveira-Carvalho et al. Circulating miR-1 as a potential biomarker of doxorubicin-induced cardiotoxicity in breast cancer patients. Oncotarget, v. 8, n. 4, p. 6994-7002, 2017Tradução . . Disponível em: https://doi.org/10.18632/oncotarget.14355. Acesso em: 04 jun. 2024.APA
Rigaud, V. O. -C., Ferreira, L. R. P., Ayub-Ferreira, S. M., Ávila, M. S., Brandão, S. M. G., Cruz, F. D., et al. (2017). Circulating miR-1 as a potential biomarker of doxorubicin-induced cardiotoxicity in breast cancer patients. Oncotarget, 8( 4), 6994-7002. doi:10.18632/oncotarget.14355NLM
Rigaud VO-C, Ferreira LRP, Ayub-Ferreira SM, Ávila MS, Brandão SMG, Cruz FD, Santos MHH, Cruz CBBV, Alves MSL, Issa VS, Guimarães GV, Cunha-Neto E, Bocchi EA. Circulating miR-1 as a potential biomarker of doxorubicin-induced cardiotoxicity in breast cancer patients [Internet]. Oncotarget. 2017 ; 8( 4): 6994-7002.[citado 2024 jun. 04 ] Available from: https://doi.org/10.18632/oncotarget.14355Vancouver
Rigaud VO-C, Ferreira LRP, Ayub-Ferreira SM, Ávila MS, Brandão SMG, Cruz FD, Santos MHH, Cruz CBBV, Alves MSL, Issa VS, Guimarães GV, Cunha-Neto E, Bocchi EA. Circulating miR-1 as a potential biomarker of doxorubicin-induced cardiotoxicity in breast cancer patients [Internet]. Oncotarget. 2017 ; 8( 4): 6994-7002.[citado 2024 jun. 04 ] Available from: https://doi.org/10.18632/oncotarget.14355
